2-nitro-1-[[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-nitro-1-[[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine
• 化学式: C12H10N6O5
• 分子量: 318.25
• InChiKey: RODAAYVFYDKHGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  168
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION DANS LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DU CANCER
  申请人：TOLREMO THERAPEUTICS AG

  公开号：WO2020127200A1

  公开（公告）日：2020-06-25

  The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof Formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

  本发明涉及一种化合物(I)的公式，可选择以药学上可接受的盐、溶剂合物、共晶、互变异构体、消旋体、对映体或二对映异构体的形式存在，以及包含化合物(I)的药物组合物，以及使用化合物(I)、或药学上可接受的盐、溶剂合物、共晶、互变异构体、消旋体、对映体或二对映异构体或其混合物，在癌症治疗中使用。本发明的进一步方面包括组合疗法，其中化合物(I)以及使用化合物(I)、或药学上可接受的盐、溶剂合物、共晶、互变异构体、消旋体、对映体或二对映异构体或其混合物，与已知的抗癌剂结合使用。
• IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER
  申请人：ETH Zurich

  公开号：EP3559276A1

  公开（公告）日：2019-10-30
• DIAGNOSTIC METHOD
  申请人：Tolremo Therapeutics AG

  公开号：EP3714069A1

  公开（公告）日：2020-09-30
• HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER
  申请人：Tolremo Therapeutics AG

  公开号：EP3898614A1

  公开（公告）日：2021-10-27
• [EN] IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER<br/>[FR] IDENTIFICATION DE MÉDICAMENTS CIBLANT DES PROGRAMMES DE TOLÉRANCE AUX MÉDICAMENTS NON GÉNÉTIQUES DANS LE CANCER
  申请人：ETH ZUERICH

  公开号：WO2018115150A1

  公开（公告）日：2018-06-28

  A cell-based screening method is provided. The screening method aims to identify drugs for the treatment of cancers characterized by cells with an over-activated signalling pathway in a combination medicament with an inhibitor of the respective over-activated signalling pathway. In particular, the expression level of SOX2 is determined to identify compounds that prevent the development of resistance to inhibitors of the MAPK and EGFR pathway.